Mirna biomarkers of prostate disease
AssigneeAsuragen, Inc.
InventorsJeffrey SHELTON, Kevin KELNAR, Stephanie VOLZ, Alex ADAI, David BROWN
Life of this patent
Estimating the term…
Abstract
This application describes miRNAs that may be used as serum or plasma biomarkers for characterizing prostate disease in a patient. These miRNA biomarkers may be used alone or in combination with other markers for the diagnosis, prognosis, or monitoring of diseases such as prostate cancer.
Claims18
1-22. (canceled)
A method for characterizing whether a prostate disease in a patient is prostate cancer or benign prostatic hyperplasia (BPH), comprising the steps of:
- a. reverse transcribing a miRNA in a serum sample;
- b. amplifying the miRNA;
- c. measuring the level of the miRNA;
- d. detecting whether the level of the miRNA is elevated or reduced,
- thereby characterizing the prostate disease in the patient as prostate cancer or BPH,
- wherein the miRNA is selected from miR-1, miR-10, miR-15a, miR-15b, miR-16, miR-17-5p, miR-18a, miR-18a*, miR-19a, miR-20a, miR-20b, miR-22, miR-23a, miR-23b, miR-24, miR-25, miR-26a, miR-26b, miR-28, miR-29a, miR-29c, miR-30a-5p, miR-30b, miR-30c, miR-30d, miR-30e-3p, miR-32, miR-92, miR-93, miR-98, miR-99b, miR-103, miR-106a, miR-107, miR-122, miR-125a, miR-126, miR-130a, miR-130b, miR-132, miR-139, miR-140, miR-142-5p, miR-143, miR-145, miR-148a, miR-155, miR-181c, miR-185, miR-191, miR-192, miR-193a, miR-194, miR-195, miR-196b, miR-197, miR-199a, miR-204, miR-205, miR-206, miR-214, miR-222, miR-223, miR-224, miR-301miR-328, miR-331, miR-335, miR-339, miR-340, miR-342, miR-345, miR-361, miR-365, miR-374, miR-375, miR-422b, miR-423, miR-425, miR-483, miR-565, miR-576, miR-584, miR-638, miR-660, let-7a, let-7d, let-7f, and let-7g.
A method for characterizing whether a prostate disease in a patient is prostate cancer or benign prostatic hyperplasia (BPH), comprising the steps of:
- a. reverse transcribing a first miRNA and a second miRNA in a serum sample;
- b. amplifying the first miRNA and the second miRNA;
- c. measuring the levels of the first miRNA and the second miRNA;
- d. detecting whether the levels of the first miRNA and the second miRNA are elevated or reduced,
- thereby characterizing the prostate disease in the patient as prostate cancer or BPH,
- wherein the first and second miRNA are selected from miR-1, miR-10, miR-15a, miR-15b, miR-16, miR-17-5p, miR-18a, miR-18a*, miR-19a, miR-20a, miR-20b, miR-22, miR-23a, miR-23b, miR-24, miR-25, miR-26a, miR-26b, miR-28, miR-29a, miR-29c, miR-30a-5p, miR-30b, miR-30c, miR-30d, miR-30e-3p, miR-32, miR-92, miR-93, miR-98, miR-99b, miR-103, miR-106a, miR-107, miR-122, miR-125a, miR-126, miR-130a, miR-130b, miR-132, miR-139, miR-140, miR-142-5p, miR-143, miR-145, miR-148a, miR-155, miR-181c, miR-185, miR-191, miR-192, miR-193a, miR-194, miR-195, miR-196b, miR-197, miR-199a, miR-204, miR-205, miR-206, miR-214, miR-222, miR-223, miR-224, miR-301miR-328, miR-331, miR-335, miR-339, miR-340, miR-342, miR-345, miR-361, miR-365, miR-374, miR-375, miR-422b, miR-423, miR-425, miR-483, miR-565, miR-576, miR-584, miR-638, miR-660, let-7a, let-7d, let-7f, and let-7g.
Dependencies are inferred from the claim text.